“Unlock the Power of the Cloud: Oracle’s Latest Tools to Skyrocket Your Government Compliance Game (and Impress Your Defense Contractor Peers)”

Welcome to the Future of Compliance with Oracle Cloud Infrastructure Saving Time and Effort with CMMC Requirements Are you tired of spending countless hours manually ensuring your defense contract projects meet the strict cybersecurity requirements of the Department of Defense? Well, fret no more! Oracle has just made your life a whole lot easier with…

Read More

“Unleashing the Future: Aspen Aerogels Inc. Announces Exciting Fourth Quarter and Fiscal Year 2024 Earnings Release and Conference Call!”

Welcome to Aspen Aerogels Blog Exciting News from Aspen Aerogels NORTHBOROUGH, Mass. , Jan. 23, 2025 /PRNewswire/ — Aspen Aerogels, Inc. (NYSE: ASPN) Aspen Aerogels is proud to announce that Don Young, President & Chief Executive Officer, and Ricardo C. have made a groundbreaking announcement today. This news is set to change the game in…

Read More

“ALX Oncology’s ASPEN-06 Phase 2 Trial: Evorpacept Proves Promising for Patients with HER2-Positive Cancer”

ALX Oncology Announces Positive Data from ASPEN-06 Phase 2 Clinical Trial Exciting News for Cancer Treatment SOUTH SAN FRANCISCO, Calif., Jan. 23, 2025 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives,…

Read More

Genprex Announces First Patient Dosed in Phase 2 Expansion Portion of ACCLAIM-3 Clinical Study of REQORSA Gene Therapy in Combination with Tecentriq to Treat Small Cell Lung Cancer

Genprex Announces Enrollment of First Patient in Phase 2 Expansion Study Acclaim-3 Study Progresses Towards Interim Analysis AUSTIN, Texas , Jan. 23, 2025 /PRNewswire/ — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the first patient…

Read More